Combined targeting of soluble latent TGF-ß and a solid tumor-associated antigen with adapter CAR T cells.
CAR T cells
Immunotherapy
TGF-β
adapter CAR
Journal
Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
2022
2022
Historique:
entrez:
17
11
2022
pubmed:
18
11
2022
medline:
22
11
2022
Statut:
epublish
Résumé
Solid tumors consist of malignant and nonmalignant cells that together create the local tumor microenvironment (TME). Additionally, the TME is characterized by the expression of numerous soluble factors such as TGF-β. TGF-β plays an important role in the TME by suppressing T cell effector function and promoting tumor invasiveness. Up to now CAR T cells exclusively target tumor-associated antigens (TAA) located on the cell membrane. Thus, strategies to exploit soluble antigens as CAR targets within the TME are needed. This study demonstrates a novel approach using Adapter CAR (AdCAR) T cells for the detection of soluble latent TGF-β within the TME of a pancreatic tumor model. We show that AdCARs in combination with the respective adapter can be used to sense soluble tumor-derived latent TGF-β, both
Identifiants
pubmed: 36387056
doi: 10.1080/2162402X.2022.2140534
pii: 2140534
pmc: PMC9662194
doi:
Substances chimiques
Antigens, Neoplasm
0
Transforming Growth Factor beta
0
Oligonucleotides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2140534Informations de copyright
© 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.
Déclaration de conflit d'intérêts
Niels Werchau, Bettina Kotter, Elvira Criado-Moronati, Andre Gosselink, Nicole Cordes, Dominik Lock, Simon Lennartz, Carolin Kolbe, Nora Winter, Karin Teppert, Fabian Engert, Brian Webster, Joerg Mittelstaet, Daniel Schaefer, Mario Assenmacher, Thomas Schaser, Pierre Abramowski, Andrew D. Kaiser were employees of Miltenyi Biotec B.V. & Co. KG at the time the study was conducted. Niels Werchau, Bettina Kotter, Joerg Mittelstaet, and Andrew D. Kaiser are coinventors of a patent application focusing on sensing of soluble antigens with adapter CAR technology. Joerg Mittelstaet and Andrew D. Kaiser are coinventors of a patent application focusing on adapter CAR technology. Michael von Bergwelt-Baildon: Astellas Pharma, Bristol-Myers Squibb, Kite Gilead, Miltenyi Biotec, MOLOGEN, MSD, Novartis, Roche (Honoraria, Speakers’ Bureau, Research Funding, Travel, Accomodations, Expenses).
Références
Sci Rep. 2015 Jul 08;5:11924
pubmed: 26152796
J Biol Chem. 1995 May 5;270(18):10618-24
pubmed: 7737999
J Exp Med. 2003 Jun 16;197(12):1689-99
pubmed: 12810687
Cancer Immunol Res. 2014 Feb;2(2):154-66
pubmed: 24778279
Gene Ther. 1999 Feb;6(2):300-4
pubmed: 10435115
J Immunother Cancer. 2021 Apr;9(4):
pubmed: 33833049
J Hematol Oncol. 2021 Apr 6;14(1):55
pubmed: 33823905
Oncoimmunology. 2021 Dec 2;10(1):2003532
pubmed: 35686214
J Immunol. 2012 Oct 15;189(8):3936-46
pubmed: 22984076
Sci Immunol. 2017 May 19;2(11):
pubmed: 28763794
Front Immunol. 2020 May 15;11:940
pubmed: 32499786
BMC Res Notes. 2012 Nov 14;5:636
pubmed: 23151377
Nat Biomed Eng. 2021 Nov;5(11):1246-1260
pubmed: 34083764
PLoS One. 2014 Dec 23;9(12):e115507
pubmed: 25536077
Br J Cancer. 2007 Aug 6;97(3):398-404
pubmed: 17637685
Nature. 2011 Jun 15;474(7351):343-9
pubmed: 21677751
Sci Immunol. 2021 Mar 26;6(57):
pubmed: 33771887
Sci Rep. 2022 Feb 3;12(1):1911
pubmed: 35115587
J Biol Chem. 1988 May 5;263(13):6407-15
pubmed: 3162913
Mol Ther. 2013 Nov;21(11):2087-101
pubmed: 23939024
Cell. 2021 Dec 9;184(25):6081-6100.e26
pubmed: 34861191
Ann Oncol. 2021 Jan;32(1):120-121
pubmed: 33098996
Mol Ther. 2021 Sep 1;29(9):2691-2706
pubmed: 33974997
Proc Natl Acad Sci U S A. 1989 Dec;86(24):10024-8
pubmed: 2513569
Stem Cell Res Ther. 2021 Jan 25;12(1):81
pubmed: 33494834
Nat Commun. 2020 Nov 9;11(1):5667
pubmed: 33168818
Proc Natl Acad Sci U S A. 2019 Apr 16;116(16):7624-7631
pubmed: 30936321
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Nat Commun. 2021 Mar 5;12(1):1453
pubmed: 33674603
Cancer Immunol Res. 2021 May;9(5):583-597
pubmed: 33619119
Cancer Res. 2013 Aug 15;73(16):5016-28
pubmed: 23824740
Mol Ther. 2013 Aug;21(8):1611-20
pubmed: 23732988
J Immunol Methods. 2012 May 31;379(1-2):23-9
pubmed: 22406166
Oncogene. 2020 May;39(21):4271-4285
pubmed: 32291413
Front Immunol. 2022 Feb 09;13:832645
pubmed: 35222421
Am J Pathol. 1989 Apr;134(4):894-902
pubmed: 2705509
Immunity. 2013 Jul 25;39(1):61-73
pubmed: 23890064
Cancer Res. 1998 Mar 15;58(6):1116-9
pubmed: 9515791
Clin Cancer Res. 2020 Jun 1;26(11):2582-2594
pubmed: 31980465
Hum Gene Ther. 2001 Oct 10;12(15):1893-905
pubmed: 11589831
J Immunother. 2018 Sep;41(7):313-318
pubmed: 29985207
Br J Cancer. 2002 Oct 7;87(8):859-67
pubmed: 12373600
J Cell Biochem. 2012 Feb;113(2):410-8
pubmed: 22223425
Cancers (Basel). 2021 Sep 22;13(19):
pubmed: 34638227
Science. 1990 Mar 16;247(4948):1328-30
pubmed: 2315700
Sci Rep. 2017 Aug 30;7(1):10060
pubmed: 28855593
BMC Cancer. 2015 Mar 27;15:188
pubmed: 25879842
Cells. 2021 Mar 10;10(3):
pubmed: 33802077
Immunity. 2019 Apr 16;50(4):924-940
pubmed: 30995507
J Immunother. 2009 Apr;32(3):292-301
pubmed: 19242371
J Immunother Cancer. 2017 May 16;5:42
pubmed: 28515942
Hum Gene Ther. 2017 Oct;28(10):914-925
pubmed: 28847167
J Exp Med. 2003 Dec 15;198(12):1875-86
pubmed: 14676299
Cell. 2018 Jun 28;174(1):156-171.e16
pubmed: 29909984
Nat Chem Biol. 2018 Mar;14(3):317-324
pubmed: 29377003
Eur J Immunol. 2009 Dec;39(12):3315-22
pubmed: 19750484
Stem Cells. 1997;15(3):190-7
pubmed: 9170210
Blood. 2010 Apr 29;115(17):3508-19
pubmed: 20190192
Cancer Res. 2003 Apr 15;63(8):1860-4
pubmed: 12702574